New Dual-Action drug targets Hard-to-Treat tumors
NCT ID NCT06911489
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug that can both image and treat advanced solid tumors. The drug targets a protein called FAP found on many cancer cells. The trial involves 132 adults with advanced solid tumors who have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the treatment can shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
-
Tianjin Medical University Cancer Insititute & Hospital
RECRUITINGTianjin, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a genetic marker guide future cancer therapies in taiwan?
- AI reads tumor slides: can computer scores predict who will do well?
- No more hospital trips? video nutrition counseling tested for cancer weight loss
- Simple senior health quiz may predict chemo dangers
- Engineered immune cells take on Hard-to-Treat cancers
- New PET scan agent could predict cancer therapy success, but trial never started